Jung-Hee Kwon

Title: Innovations of Jung-Hee Kwon in Hepatocellular Carcinoma Treatment

Introduction

Jung-Hee Kwon is an accomplished inventor based in Daejeon, South Korea. He has made significant contributions to the field of molecular targeted therapy, particularly in the treatment of hepatocellular carcinoma. His innovative approach aims to enhance the effectiveness of existing treatments for patients suffering from this challenging condition.

Latest Patents

Jung-Hee Kwon holds a patent for an analytical method designed to increase susceptibility to molecular targeted therapy in hepatocellular carcinoma. This method involves analyzing the mRNA expression of FGFR1, along with other biomarkers such as VEGFR2, PDGFRβ, c-KIT, c-RAF, EGFR, and mTOR. By determining whether a patient has susceptibility or resistance to sorafenib treatment, this analytical method allows for more personalized and effective treatment strategies.

Career Highlights

Kwon is currently associated with Cbs Bioscience, Co., Ltd., where he continues to develop innovative solutions in cancer treatment. His work is pivotal in advancing the understanding of how specific biomarkers can influence treatment outcomes for patients with hepatocellular carcinoma.

Collaborations

Jung-Hee Kwon collaborates with notable colleagues in his field, including Jin-Young Park and Young-Ho Moon. Their combined expertise contributes to the ongoing research and development of effective therapies for cancer patients.

Conclusion

Jung-Hee Kwon's innovative work in the field of hepatocellular carcinoma treatment exemplifies the importance of personalized medicine. His analytical method for assessing treatment susceptibility represents a significant advancement in cancer therapy.